Clinical Trial Update: A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

First-in-human Phase 1 dose-escalation study of JAB-3068, an SHP2 inhibitor, in adults with advanced solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Head and Neck Cancer
• Non-small Cell Lung Cancer
• Solid Tumors

Drugs mentioned

• JAB-3068 (SHP2 inhibitor)

Snippet

Sponsor: Jacobio Pharmaceuticals Co., Ltd. | Conditions: Non-small Cell Lung Cancer, Head and Neck Cancer | Phase 1 | Status: COMPLETED